Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines
Open accessAbstract
yocarditis is recognized as a rare complication of coronavirus disease 2019 (COVID-19) vaccinations, especially in young adult men and adolescent boys.1,2 Incidence is approximatel 1 to 5 cases among 100 000 in the general population, and 1 in 20 000 among those16 to 30 years of age. 2 Cases most often occur days after the second vaccine dose and are usually mild and self-limited.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
None of the participants reported any signs or symptoms of myocarditis that would warrant further investigation.
“None of the participants reported any signs or symptoms of myocarditis that would warrant further investigation, which is expected given the incidence of 1–5 cases per 100,000 in the general population12.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [12]
The absence of myocarditis signs or symptoms is expected given the incidence of 1-5 cases per 100,000 in the general population.
“None of the participants reported any signs or symptoms of myocarditis that would warrant further investigation, which is expected given the incidence of 1–5 cases per 100,000 in the general population12.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027 · see citing works
Myocarditis With COVID-19 mRNA Vaccines
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021) · Circulation · doi:10.1161/circulationaha.121.056135 · Cited by 854 · see citing works
Self-citationPatone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar‐Hari, M., Watkinson, P., Khunti, K. K., Harnden, A., Coupland, C. A. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01630-0 · Cited by 641 · see citing works
Vojdani, A., & Kharrazian, D. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108480 · Cited by 589 · see citing works
Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7038e1 · Cited by 406 · see citing works
Heinz, F. X., & Stiasny, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00369-6 · Cited by 362 · see citing works
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321 · see citing works
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
Trougakos, I. P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., Kastritis, E., Andreakos, E., & Dimopoulos, M. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.007 · Cited by 273 · see citing works
Kanduc, D., & Shoenfeld, Y. (2020) · Immunologic Research · doi:10.1007/s12026-020-09152-6 · Cited by 263 · see citing works
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar‐Hari, M., Watkinson, P., Khunti, K. K., Harnden, A., Coupland, C. A. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059970 · Cited by 238 · see citing works
Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis
Yonker, L. M., Swank, Z., Bartsch, Y. C., Burns, M. D., Kane, A. S., Boribong, B. P., Davis, J. P., Loiselle, M., Novak, T., Senussi, Y., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061025 · Cited by 230 · see citing works
Ogata, A. F., Cheng, C., Desjardins, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab465 · Cited by 217 · see citing works
Ling, R. R., Ramanathan, K. R., Tan, F. L., Tai, B. C., Somani, J., Fisher, D. A., & MacLaren, G. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00059-5 · Cited by 166 · see citing works
Avolio, E., Carrabba, M., Milligan, R., Williamson, M. K., Beltrami, A. P., Gupta, K., Elvers, K. T., Gamez, M., Foster, R. R., Gillespie, K. M., et al. (2021) · Clinical Science · doi:10.1042/cs20210735 · Cited by 144 · see citing works
A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination
Murphy, W. J., & Longo, D. L. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2113694 · Cited by 121 · see citing works
Li, C., Chen, Y., Zhao, Y., Lung, D. C., Ye, Z., Song, W., Liu, F., Cai, J., Wong, W., Yip, C. C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab707 · Cited by 109 · see citing works
Vaccine mRNA Can Be Detected in Blood at 15 Days Post-Vaccination
Fertig, T. E., Chiţoiu, L., Marta, D. S., Ionescu, V., Cismasiu, V. B., Radu, E., Angheluta, G., Dobre, M., Serbanescu, A., Hinescu, M. E., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071538 · Cited by 71 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Saraf, A., Gurjar, R., Kaviraj, S., Kulkarni, A., Kumar, D., Kulkarni, R., Virkar, R., Krishnan, J., Yadav, A., Baranwal, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02955-2 · Cited by 66 · see citing works
“None of the participants reported any signs or symptoms of myocarditis that would warrant further investigation, which is expected given the incidence of 1–5 cases per 100,000 in the general population 12 .”
- Authors
- Bozkurt, B.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Bozkurt, Biykem
- ORCID
- Bozkurt, Biykem
- Venue
- Circulation
- Published
- 2023-03-14
- Volume
- 147
- Issue
- 11
- Pages
- 877-880
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC10010664
- OpenAlex
- W4321002532
- Cited by
- 20
- References
- 18
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 13 · 2023: 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- myocarditis, COVID-19 mRNA vaccine, vaccine adverse events, pathogenesis, young men, adolescent boys, second vaccine dose, SARS-CoV-2
- MeSH terms
- COVID-19, COVID-19 Vaccines, Humans, Myocarditis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
